homepage-top-section

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a rolling review of molnupiravir (MK-4482 and EIDD-2801), an investigational oral antiviral medicine,

The European Commission (EC) has approved Merck’s Keytruda (pembrolizumab) plus chemotherapy combination to treat triple-negative breast cancer (TNBC) patients. Keytruda, an anti-programmed death receptor-1 (PD-1) therapy, blocks the

Clinical-stage biotechnology firm Atreca has signed a licensing agreement with the Bill & Melinda Gates Medical Research Institute (Gates MRI) for the development of a monoclonal antibody to

The Russia Ministry of Health has approved BeiGene’s Brukinsa (zanubrutinib) to treat patients with relapsed or refractory mantle cell lymphoma (MCL). Brukinsa is Bruton’s tyrosine kinase (BTK) molecule

Moleculin Biotech has received authorisation to begin a Phase Ia clinical trial of its drug, WP1122, in the UK to treat Covid-19. The approval was obtained from the

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved two additional production sites for making Pfizer-BioNTech’s Covid-19 vaccine, Comirnaty. Both the facilities

Silence Therapeutics has announced collaboration with Hansoh Pharmaceutical to develop new therapeutics using Silence’s mRNAi GOLD platform. As part of the collaboration, the companies will develop novel short

Exelixis has signed an exclusive collaboration and license agreement with STORM Therapeutics to discover and develop inhibitors of novel RNA modifying enzymes. Initially, the companies will focus on

The US Food and Drug Administration (FDA) has approved biologics license application (sBLA) and the European Medicines Agency (EMA) has validated the type-II variation application for Novartis’ Beovu